BioNTech
NEWS
The United States and other wealthy nations now stand at an important place in their COVID-19 vaccine campaigns. The question largely turns to vaccinating the remainder of the population – namely, those under 12 years.
Pfizer has reported several highlights regarding its mRNA COVID-19 vaccine. As the world deal with rising Delta variant cases, Pfizer-BioNTech is still arguing that a third booster shot will be likely.
Moderna continues to assess its COVID-19 vaccine in juveniles, the company is expanding the study to include protocols to detect the potential of rare side effects, including heart inflammation.
The company announced its Malaria project, part of the “eradicateMalaria” initiative led by the kENUP Foundation.
With COVID-19 resurging in the U.S., particularly in states with the lowest vaccination rates, additional news and research about the vaccines and the virus is coming out. Here’s a look.
The FDA has now approved AstraZeneca’s convenient once-a-week glucose lowering drug for 10 to 17-year-olds with type 2 diabetes.
As COVID-19 begins yet another surge across the U.S., there is some promising news about the effectiveness of vaccines. Here’s a look at some top COVID-19 stories.
The company also reported on its COVID-19 vaccine production with CureVac, a drug it is abandoning, and a few specific drug updates.
The lawsuit alleges that Ocugen made “materially false and misleading statements” about its operations and compliance policies.
JOBS
IN THE PRESS